CPA
MGX icon

Capital Performance Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Capital Performance Advisors’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$11 – 2784
2024
Q3 		$11 Buy
+5
New +$17 ﹤0.01% 2881

Other funds holding MGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Capital Performance Advisors's MGX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Metagenomi Therapeutics (MGX) in Q4 2024, closing a stake of 5 shares — an estimated $11 sold.

Capital Performance Advisors first reported a position in MGX in Q3 2024 and held it in 1 quarter. The position peaked at $11 in Q3 2024. 77 funds tracked by Wall St. Rank hold MGX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Metagenomi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 5 Metagenomi Therapeutics shares in Q4 2024, an estimated $11.
  • Capital Performance Advisors first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Metagenomi Therapeutics position peaked at $11 in Q3 2024.
  • 77 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.